Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01822496 · MORE INFO

Limitations, agreements, and source contact

Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer · Source last updated 2019-08-05

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
other Details
Must obtain prior Sponsor approval.
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
limitations And Caveats
description
This study stopped accrual early due to unmet targeted accrual goals with 59 subjects accrued out of 234 planned.
point Of Contact
email
seiferheldw@nrgoncology.org
organization
NRG Oncology
phone
215-574-3208
title
Wendy Seiferheld
Complete source fields
certain Agreement
other Details
Must obtain prior Sponsor approval.
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
limitations And Caveats
description
This study stopped accrual early due to unmet targeted accrual goals with 59 subjects accrued out of 234 planned.
point Of Contact
email
seiferheldw@nrgoncology.org
organization
NRG Oncology
phone
215-574-3208
title
Wendy Seiferheld

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice